

CHRISTINA TREPPENDAHL

601-366-0855 • ctreppendahl@mississippimigrainecenter.com • Ridgeland, MS 39157

SUMMARY

Headache specialist with over 11 years of clinical experience with primary and secondary headache disorders. Founder and director of a large private specialty headache practice with multiple providers. Key opinion leader for all pharmaceutical companies investigating and promoting pharmaceuticals and devices in migraine and cluster treatment. Principal investigator in multiple phase III clinical trials for migraine, cluster, and medication overuse headache. National and international clinical expert in headache diagnosis and management.

SKILLS

- Specializing in Headache Disorders
- Clinic Administration
- Clinical Instruction
- Patient safety
- Pediatrics
- Interdisciplinary team coordination
- Assessment skills
- Diagnosing patients
- Treatment plan development
- Pharmaceutical prescription
- Patient counseling
- In-office procedures: Botox, nerve blocks, IV infusions, injections
- Accreditation support
- Fundraising and major donor development
- Clinical research experience: GCP and C-SSRS certification

EXPERIENCE

Principal Investigator

Headache Neurology Research Institute | Ridgeland, MS | May 2016-Current

Founder and Director

The Headache Center | Ridgeland, MS | May 2013-Current

Family Nurse Practitioner

Mississippi Headache Center | Jackson, MS | May 2010-Apr 2013

Family Nurse Practitioner

Central Mississippi Medical Center | Jackson, MS | Aug 2009-Feb 2010

Registered Nurse

Central Mississippi Medical Center | Jackson, MS | Jun 2008-Jul 2009

Neonatal Nurse Practitioner

Newborn Associates | Jackson, MS | Jan 2003-May 2008

Neonatal Nurse Practitioner

University of Mississippi Medical Center | Jackson, MS | Aug 1998-Dec 2002

EDUCATION AND TRAINING

Master of Science: Headache Disorders

University of Copenhagen | Denmark | Jun 2020

Master of Science: Family Nurse Practitioner

Mississippi University for Women | Columbus, MS | Jul 2009

Master of Science: Neonatal Nurse Practitioner

Vanderbilt University | Nashville, TN | Jul 1998

ACTIVITIES AND HONORS

- American Headache Society
- International Headache Society
- National Headache Foundation
- Southern Headache Society
- Headache Cooperative of New England
- Headache Cooperative of the Pacific
- World Headache Society
- American Academy of Nurse Practitioners
- MIGRAINE WORLD SUMMIT (Headache Expert 2020)
- America's Top Nurse Practitioners (Winner 2018)
- Certificate of Added Qualification in Headache Medicine National Headache Foundation 2015-current
- Sigma Theta Tau International Honor Society Vanderbilt University (1997)

CONSULTANT/ADVISOR/SPEAKER BUREAU

Abbvie

Allergan

American Academy of Nurse Practitioners

Amgen

Avanir Pharmaceuticals

Depomed, Inc.

Electrocore

Ely Lilly

Impax Labs

Impel NeuroPharma

Iroko Pharmaceuticals

Novartis

National Headache Foundation

Nautilus Neurosciences, Inc.

Pernix

Promius Pharma
Supernus Pharmaceuticals
Southern Headache Society
Teva Pharmaceutical Industries, Inc.
Upsher-Smith Laboratories
Zogenix, Inc.

CLINICAL TRIALS

Allergan

A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for The Prevention of Migraine In Participants with Chronic or Episodic Migraine. Phase III. Protocol 3101-312-002. Principal Investigator. February 2021-Current

Lundbeck

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Delayed-start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients with Episodic Cluster Headache. Phase III. Protocol 19386A. Principal Investigator. December 2020-Current

TEVA

A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice. Phase IV. Protocol TV48125-MH-50039. Principal Investigator. November 2020-Current

TEVA

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase III. Protocol TV48125-CNS-30084. Principal Investigator. October 2020-Current

TEVA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase III. Protocol TV48125-CNS-30083. Principal Investigator. October 2020-Current

TEVA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age. Phase III. Protocol TV48125-CNS-30082. Principal Investigator. October 2020-Current

Novartis

Assessment of Prolonged Safety and tolerability in Migraine Patients in a Long-term Open-label Study. Phase IV. Principal Investigator. July 2020-Current

Theranica

Efficacy and Safety of Nerivio™, a Remote Electrical Neuromodulation Device, for Acute Treatment of Migraine in People with Chronic Migraine: an Open Label, Single Arm, Multicenter Study. Protocol THC006. Principal Investigator. January 2020-August 2020

Alder

A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine. Phase III. Protocol ALD403-CLIN-015. Principal Investigator. December 2019-September 2020

Novartis

A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab vs. Oral Prophylactics) in Adult Episodic Migraine Patients. Phase IV. Protocol AMG334A2401. Principal Investigator. April 2019-Present

Allergan

A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Episodic Migraine. Phase III. Protocol 3101-309-002. Principal Investigator. April 2019-Present

Allergan

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress). Phase III. Protocol 3101-303-002. Principal Investigator. March 2019-Present

Allergan

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Episodic Migraine (Advance). Phase III. Protocol 3101-301-002. Principal Investigator. January 2019-August 2020

ElectroCore

A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II) Phase III. Protocol GPI-US-10. Principal Investigator. January 2019-September 2020

Mayo Clinic

Determining the Optimal Treatment Strategy for Patients Who Have Chronic Migraine with Medication Overuse.

Protocol 16-001036. Principal Investigator. July 2017-Present

Allergan

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogapant in the Acute Treatment of Migraine. Protocol UBR-MD-02. Principal Investigator. December 2016-March 2019

Allergan

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogapant in the Acute Treatment of Migraine with or Without Aura. Phase III. Protocol UBR-MD-04. Principal Investigator. December 2016-August 2018

Avanir Pharmaceuticals

A Randomized Pilot Study of Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine. Phase II. Protocol 14-001AV. Principal Investigator. August 2016-April 2018

SCIENTIFIC PRESENTATIONS/PUBLICATIONS

- Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials *Neurology and Therapy*. 2021
- Schwedt TJ, Hentz JG, Sahai-Srivastava S, Spare NM, Martin VT, Treppendahl C, Digre K, Bennett NL, Birlea M, Watson D, Murinova N, Robert T, Dodick DW; MOTS Investigators. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. *Headache*. 2021 Jan 12. doi: 10.1111/head.14056. Epub ahead of print. PMID: 33432635.
- Brandes, J, Ramirez-Campos V, Yang R, Cohen Jul, Galic M, X N, Treppendahl C. Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study (2019). Submitted for presentation at XIX Congress of the International Headache Society, Dublin, Ireland. (abstract)
- Hutchinson S, Dodick DW, Treppendahl C, Bennett N, Yu SY, Guo H, Trugman JM. (2019) Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies. Submitted for presentation at XIX Congress of the International Headache Society (abstract)
- Schwedt TJ, Spare NPI, Martin VT, Treppendahl C, Bennett NL, Birlea M, DeLange JM, Hentz JG, Roberts T, Dodick DW (2019). The Medication Overuse Treatment Strategy (MOTS) Trial: Description of the Patient Cohort at Baseline. Submitted for presentation at the annual scientific meeting of the American Headache Society, Philadelphia, PA. (abstract)
- Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ. "The Emerging Role of GammaCore® in the Management of Cluster Headache: Expert Panel Recommendations." *The American Journal of Managed Care*, Ascend Media, 1 Nov. 2017, mayoclinic.pure.elsevier.com/en/publications/the-emerging-role-of-gammacore-in-the-management-of-cluster-heada.